Reaction
Discharge reporting signals
As of the last recalculation, Discharge appears in 1,349 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 21.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab-Dyyb | 39 | 21.2 | 21.2 |
| Inclisiran | 10 | 19.4 | 19.4 |
| Dicyclomine Hydrochloride | 16 | 17.5 | 17.5 |
| Human Immunoglobulin G | 23 | 17.5 | 17.5 |
| Ketoprofen | 14 | 16.6 | 16.6 |
| Tolterodine Tartrate | 9 | 15.6 | 15.6 |
| Dalteparin Sodium | 8 | 11.7 | 11.7 |
| Epoprostenol | 9 | 10.7 | 10.7 |
| Itraconazole | 8 | 10.6 | 10.6 |
| Orlistat | 14 | 8.4 | 8.4 |
| Prochlorperazine Maleate | 5 | 8.4 | 8.4 |
| Canakinumab | 5 | 7.2 | 7.2 |
| Tobramycin | 11 | 7.1 | 7.1 |
| Alpelisib | 4 | 7.1 | 7.1 |
| Secukinumab | 69 | 6.9 | 6.9 |
| Nemolizumab-Ilto | 5 | 6.1 | 6.1 |
| Cabotegravir | 3 | 5.7 | 5.7 |
| Siponimod | 3 | 5.2 | 5.2 |
| Copper | 12 | 4.3 | 4.3 |
| Dupilumab | 122 | 4.2 | 4.2 |
| Lifitegrast | 4 | 3.8 | 3.8 |
| Bimekizumab | 4 | 2.9 | 2.9 |
| Salicylic Acid | 6 | 1.8 | 1.8 |
| Adapalene | 20 | 1.7 | 1.7 |
| Pimavanserin Tartrate | 5 | 1.4 | 1.4 |